Enadoline: Difference between revisions
Content deleted Content added
No edit summary |
Panoramix303 (talk | contribs) m references fixed, break in the IUPAC name for better view |
||
| Line 1: | Line 1: | ||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = 2-(benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5] decan-8-yl)ethanamide |
| IUPAC_name = 2-(benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7- |
||
(pyrrolidin-1-yl)-1-oxaspiro[4.5] decan-8-yl)ethanamide |
|||
| image = Enadoline2d.png |
| image = Enadoline2d.png |
||
| width = |
| width = 200px |
||
| CAS_number = 124378-77-4 |
| CAS_number = 124378-77-4 |
||
| ATC_prefix = |
| ATC_prefix = |
||
| Line 28: | Line 29: | ||
'''Enadoline''' is a drug which acts as a highly selective [[kappa opioid receptor|κ-opioid]] [[agonist]]. |
'''Enadoline''' is a drug which acts as a highly selective [[kappa opioid receptor|κ-opioid]] [[agonist]]. |
||
In human studies, it produced visual distortions and feelings of [[dissociation]], reminiscent of the effects of [[Salvinorin-A]]. |
In human studies, it produced visual distortions and feelings of [[dissociation]], reminiscent of the effects of [[Salvinorin-A]].<ref name="pmid11594439">{{cite journal |
||
|author=Walsh SL, Strain EC, Abreu ME, Bigelow GE |
|||
|title=Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans |
|||
|journal=Psychopharmacology (Berl.) |
|||
|volume=157 |
|||
|issue=2 |
|||
|pages=151–62 |
|||
|year=2001 |
|||
|pmid=11594439 |
|||
|doi= |
|||
}}</ref> |
|||
It was looked at as a potential [[analgesic]], but abandoned because of the dose-limiting effects of [[dysphoria]], which could be expected from a κ-opioid agonist. There was mention of its potential in treating [[coma]]tose head injury or [[stroke]] victims, where that type of side effect would be immaterial. |
It was looked at as a potential [[analgesic]], but abandoned because of the dose-limiting effects of [[dysphoria]], which could be expected from a κ-opioid agonist. There was mention of its potential in treating [[coma]]tose head injury or [[stroke]] victims, where that type of side effect would be immaterial.<ref name="pmid15989506">{{cite journal |
||
|author=Barber A, Gottschlich R |
|||
<ref>{{cite journal| journal=NCBI | title=Novel developments with selective, non-peptidic kappa-opioid receptor agonists. | url=http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15989506&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum}}</ref> |
|||
|title=Novel developments with selective, non-peptidic kappa-opioid receptor agonists |
|||
|journal=Expert Opin Investig Drugs |
|||
|volume=6 |
|||
|issue=10 |
|||
|pages=1351–68 |
|||
|year=1997 |
|||
|pmid=15989506 |
|||
|doi=10.1517/13543784.6.10.1351 |
|||
}}</ref> |
|||
{{pharma-stub}} |
{{pharma-stub}} |
||
Revision as of 11:02, 18 December 2007
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H32N2O3 |
| Molar mass | 396.52 g/mol g·mol−1 |
Enadoline is a drug which acts as a highly selective κ-opioid agonist.
In human studies, it produced visual distortions and feelings of dissociation, reminiscent of the effects of Salvinorin-A.[1]
It was looked at as a potential analgesic, but abandoned because of the dose-limiting effects of dysphoria, which could be expected from a κ-opioid agonist. There was mention of its potential in treating comatose head injury or stroke victims, where that type of side effect would be immaterial.[2]
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
See also
References
- ^ Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001). "Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans". Psychopharmacology (Berl.). 157 (2): 151–62. PMID 11594439.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Barber A, Gottschlich R (1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opin Investig Drugs. 6 (10): 1351–68. doi:10.1517/13543784.6.10.1351. PMID 15989506.